How Argent’s CannPal Acquisition Could Accelerate CannEpil’s Global Reach
Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.
- Acquisition of 48% equity interest in CannPal for $2 million in RGT shares
- Option secured to acquire Neuvis® drug-delivery platform intellectual property
- Deal supersedes previous broader term sheet, focusing on core assets
- Supports regulatory and commercial pathways for CannEpil® in Europe and beyond
- Board changes include Andrew Chapman joining as Executive Director
A Sharpened Strategic Acquisition
Argent BioPharma has taken a decisive step to strengthen its clinical pipeline and intellectual property portfolio by signing a binding agreement to acquire AusCann’s 48% equity interest in CannPal Animal Therapeutics. This streamlined transaction replaces a broader, non-binding term sheet announced in August 2025, focusing sharply on assets that directly enhance Argent’s flagship cannabinoid pharmaceutical, CannEpil®.
The acquisition consideration involves issuing 20 million Argent shares at 10 cents each, subject to shareholder approval and a three-month escrow period. This capital-efficient deal is fully supported by Argent’s board, major shareholders, and its primary financier, C/M Capital Partners, who recently extended an $11 million financing facility.
Clinical and Commercial Implications
CannPal’s validated preclinical and real-world data are expected to accelerate CannEpil®’s regulatory submissions and early-access programs, particularly in Europe. The acquisition also positions Argent to benefit from CannPal’s veterinary partnerships, potentially generating non-dilutive cash flows that could bolster financial flexibility ahead of Argent’s planned U.S. national exchange dual listing.
Moreover, Argent has secured an option to acquire the Neuvis® drug-delivery platform intellectual property, a patented oral capsule technology that promises enhanced bioavailability and lifecycle management for both CannEpil® and CimetrA®. This platform could extend Argent’s IP protection well into the late 2030s, underpinning future product iterations and commercial value.
Governance and Growth Outlook
Following completion, Andrew Chapman, an experienced capital markets and biotech executive, will join Argent’s board as an Executive Director, while current CEO Roby Zomer will transition to Non-Executive Chairman. This leadership reshuffle aligns with Argent’s ambitions to expand its footprint in North America and integrate the newly acquired assets effectively.
The transaction is expected to complete in the first quarter of 2026, pending shareholder approval, with integration activities already planned to support clinical expansion and market readiness. Recent U.S. federal policy shifts under the Trump Administration may further enhance the regulatory environment for medical cannabis and CBD, potentially opening new commercial and partnership avenues for Argent.
A Focused Path Forward
By honing in on high-value assets and securing optional technology platforms, Argent BioPharma is positioning itself to navigate the complex cannabinoid pharmaceutical landscape with greater agility. The deal reflects a pragmatic approach to growth, balancing immediate clinical benefits with longer-term IP-driven value creation.
Bottom Line?
Argent’s focused acquisition and board refresh set the stage for accelerated clinical progress and strategic U.S. market entry.
Questions in the middle?
- Will Argent exercise the option to acquire the Neuvis® drug-delivery platform within the next 12 months?
- How will the share issuance impact Argent’s capital structure and shareholder dilution?
- What are the timelines and milestones for integrating CannPal’s data into CannEpil®’s regulatory submissions?
